dehydroepiandrosterone has been researched along with gefitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, K; Nishio, M; Ohyanagi, F; Okumura, S; Satoh, Y | 1 |
1 trial(s) available for dehydroepiandrosterone and gefitinib
| Article | Year |
|---|---|
Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Testosterone | 2005 |
1 other study(ies) available for dehydroepiandrosterone and gefitinib
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |